{"doi":"10.1016/j.antiviral.2009.07.022","title":"Entry inhibitors in the treatment of HIV-1 infection","abstract":null,"journal":"Antiviral Research","year":2010,"id":19324,"datarank":9.565203797292483,"base_score":5.308267697401205,"endowment":5.308267697401205,"self_citation_contribution":0.7962401546101808,"citation_network_contribution":8.768963642682301,"self_endowment_contribution":0.7962401546101808,"citer_contribution":8.768963642682301,"corpus_percentile":null,"corpus_rank":null,"citation_count":201,"citer_count":196,"citers_with_citation_signal":171,"citers_with_endowment":171,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":131313,"name":"Robert W. Doms","orcid":null,"position":1,"is_corresponding":false},{"id":131311,"name":"John C. Tilton","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":5.308267697401205,"endowment":5.308267697401205,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19683546","pmcid":null,"openalex_id":"https://openalex.org/W2014733693","authors":[],"funders":[],"total_grants":0,"fwci":9.4029,"citation_percentile":0.98634812,"influential_citations":11,"citation_trend":[{"year":2012,"count":37},{"year":2013,"count":33},{"year":2014,"count":11},{"year":2015,"count":19},{"year":2016,"count":11},{"year":2017,"count":8},{"year":2018,"count":8},{"year":2019,"count":3},{"year":2020,"count":4},{"year":2021,"count":5},{"year":2022,"count":3},{"year":2023,"count":1},{"year":2024,"count":5},{"year":2025,"count":4}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0166354209003945?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0166354209003945?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.antiviral.2009.07.022","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/19683546","host_type":"repository"}],"fields_of_study":["HIV Research and Treatment","HIV/AIDS drug development and treatment","HIV/AIDS Research and Interventions","Medicine","Cyclohexanes","Drug Resistance, Viral","Enfuvirtide","HIV Envelope Protein gp41","HIV Fusion Inhibitors","HIV Infections","HIV-1","History, 20th Century","History, 21st Century","Humans","Maraviroc","Peptide Fragments","Triazoles"],"mesh_terms":["Enfuvirtide","Maraviroc","Cyclohexanes","Humans","Peptide Fragments","Triazoles","HIV-1","HIV Infections","HIV Envelope Protein gp41","HIV Fusion Inhibitors","Drug Resistance, Viral","History, 20th Century","History, 21st Century"],"keywords":["Enfuvirtide","Maraviroc","Entry inhibitor","Viral entry","Human immunodeficiency virus (HIV)","CCR5 receptor antagonist","Drug","Medicine","Virology","Antiretroviral therapy","Pharmacology","Immunology","Viral replication","Viral load","Virus","Gp41","Antigen"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-04T03:17:06.633854Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}